| Literature DB >> 31692590 |
Mahmood Yaseen Hachim1, Ibrahim Yaseen Hachim2, Noha M Elemam1, Rifat A Hamoudi1,2,3.
Abstract
BACKGROUND: : With the increasing incidence of asthma, more attention is focused on the diverse and complex nutritional and environmental triggers of asthma exacerbations. Currently, there are no established risk assessment tools to evaluate asthma triggering potentials of most of the nutritional and environmental triggers encountered by asthmatic patients.Entities:
Keywords: GSEA; chemical-induced asthma; toxicogenomic; transcriptomic
Year: 2019 PMID: 31692590 PMCID: PMC6717055 DOI: 10.2147/PGPM.S217535
Source DB: PubMed Journal: Pharmgenomics Pers Med ISSN: 1178-7066
Figure 1Flowchart outlining the steps of the bioinformatics approach to identify differentially expressed genes in severe asthmatic bronchial epithelium compared to healthy controls.
Abbreviations: GEO omnibus, Gene Expression Omnibus; RMA, Robust Multiarray Averaging; GC-RMA, GeneChip RMA; MAS5, Affymetrix Microarray Suite 5.
Figure 2The flowchart of the bioinformatics approach to identify gene sets related to chemical, toxins, and drugs.
Details of datasets extracted from DSigDB and DrugMatrix and used for GSEA
| Collection | Description | Unique Number of Genes | Number of Gene Sets |
|---|---|---|---|
| D1: FDA Approved | FDA Approved Drug Gene Sets. | 1,288 | 1,202 |
| D2: Kinase Inhibitors | Kinase Inhibitors Gene Sets based on in vitro kinase profiling assays. | 407 | 1,220 |
| FDA | FDA Approved Kinase Inhibitors. | 341 | 28 |
| HMS LINCS | Kinase inhibition assays extracted from HMS LINCS database. | 381 | 90 |
| MRC | Kinase inhibition assays extracted from MRC Kinome Inhibition database. | 137 | 157 |
| GSK | GSK Published Kinase Inhibitor Set (PKIS), kinase inhibitors used as chemical probes. | 116 | 204 |
| Roche | Kinase Inhibitors profiled by Roche. | 153 | 570 |
| RBC | Kinase Inhibitors profiled by Reaction Biology Corporation. | 246 | 99 |
| KinomeScan | Kinase Inhibitors profiled by DiscoveryRx using KinomeScan technology. | 374 | 72 |
| D3: Perturbagen Signatures | 7,064 gene expression profiles from three cancer cell lines perturbed by 1,309 compounds from CMap (build 02). | 11,137 | 1,998 |
| CMAP | 7,064 gene expression profiles from three cancer cell lines perturbed by 1,309 compounds from CMap (build 02). | 11,137 | 1,998 |
| D4: Computational Drug Signatures | Drug signatures extracted from literature using a mixture of manual curation and by automatic computational approaches. | 18,854 | 18,107 |
| BOSS | Text mining approaches of drug-gene targets using Biomedical Object Search System (BOSS). | 3,354 | 2,114 |
| CTD | Curation of targets from Comparative Toxicogenomics Database (CTD). | 18,700 | 5,163 |
| TTD | Manual curation of targets from the Therapeutics Targets Database (TTD). | 1,389 | 10,830 |
| DrugMatrix database | The DrugMatrix database is one of the world’s largest toxicogenomic reference resources | 5209 | 7876 |
Figure 3The flowchart outline using the Comparative Toxicogenomics Database (CTD) batch query tool (http://ctdbase.org/tools/batchQuery) to identify common pathways targeted by most of the GSEA-identified chemicals. (A) All the earlier identified drugs and chemicals were uploaded to the query tool to search for genes and (B) pathways that were documented to be affected by queried chemicals. The tool will generate (C) a list of pathways where the given chemical affects genes related to that pathway significantly (adjusted p-value <0.05). (D) Only pathways that are shared by at least 50 percent and above of the identified chemicals are selected.
Figure 4Gene Set Enrichment Analysis (GSEA) of the differentially expressed genes between severe asthmatic bronchial epithelium (n=22) and healthy bronchial epithelium (n=37) in GSE64913. (A) Distribution of the identified genes ranked according to their position (B) Heatmap image generated from the 2952 DEG between severe asthma and healthy controls which were later filtered into 225 genes (C) the top enriched pathways whether upregulated or downregulated in severe asthma compared to healthy controls using metascape (http://metascape.org): a gene annotation and analysis online resource that generates a graphical representation.
List of the significantly enriched pathways related to chemicals, toxins, and drugs for the genes that showed significant differential expression in severe asthmatic bronchial epithelium compared to healthy controls
| # | Gene Set Name | Size | Enrichment score | Normalized Enrichment score | Nominal | False Discovery Rate q-value | Familywise-error rate | Rank at Max | Leading Edge |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Purpurogallin | 28 | 0.630629 | 1.827431 | 0.002024292 | 0.0122542 | 0.033 | 1538 | tags=64%, list=26%, signal=86% |
| 2 | Tyrphostin AG 538 | 16 | 0.631126 | 1.846969 | 0.003937008 | 0.0136133 | 0.028 | 797 | tags=38%, list=13%, signal=43% |
| 3 | 7-amino-4-hydroxy-2-naphthalenesulfonic acid | 15 | 0.640253 | 1.799482 | 0.002016129 | 0.0146326 | 0.049 | 176 | tags=27%, list=3%, signal=27% |
| 4 | Corilagin | 17 | 0.676499 | 1.8472 | 0.003898636 | 0.02042 | 0.028 | 964 | tags=53%, list=16%, signal=63% |
| 5 | 4-hydroxytamoxifen | 17 | 0.588731 | 1.724107 | 0.012219959 | 0.0285716 | 0.096 | 699 | tags=35%, list=12%, signal=40% |
| 6 | Salazinic Acid | 15 | 0.646698 | 1.672565 | 0.011857707 | 0.0403463 | 0.147 | 1700 | tags=73%, list=28%, signal=102% |
| 7 | Ellagic Acid | 27 | 0.559782 | 1.639618 | 0.004008016 | 0.0463795 | 0.183 | 1067 | tags=48%, list=18%, signal=58% |
| 8 | Baicalein | 15 | 0.607701 | 1.556171 | 0.032719836 | 0.076446 | 0.273 | 1067 | tags=47%, list=18%, signal=57% |
| 9 | Curcumin | 25 | 0.542949 | 1.509353 | 0.024439918 | 0.0802608 | 0.333 | 978 | tags=48%, list=16%, signal=57% |
| 10 | SB 202190 | 22 | 0.489577 | 1.518684 | 0.032258064 | 0.082731 | 0.323 | 699 | tags=36%, list=12%, signal=41% |
| 11 | Acrylamide | 15 | 0.586047 | 1.661663 | 0.009451796 | 0.1950874 | 0.477 | 125 | tags=20%, list=2%, signal=20% |
| 12 | Myricetin | 40 | 0.547651 | 1.654645 | 0.01713062 | 0.1982278 | 0.487 | 1174 | tags=48%, list=20%, signal=59% |
| 13 | Cupric Oxide | 131 | 0.413138 | 1.663593 | 0.012526096 | 0.2041864 | 0.471 | 936 | tags=29%, list=16%, signal=34% |
| 14 | Microcystin RR | 20 | 0.547977 | 1.66728 | 0.00990099 | 0.2108996 | 0.462 | 462 | tags=25%, list=8%, signal=27% |
| 15 | Arachidonic Acid | 78 | 0.524402 | 1.64341 | 0.004115226 | 0.212851 | 0.518 | 998 | tags=38%, list=17%, signal=46% |
| 16 | 16 | 0.667372 | 1.550415 | 0.02586207 | 0.2191059 | 0.681 | 1328 | tags=69%, list=22%, signal=88% | |
| 17 | Luteolin | 44 | 0.54766 | 1.634669 | 0.024844721 | 0.2199198 | 0.532 | 1012 | tags=43%, list=17%, signal=52% |
| 18 | Ammonium Hexachloroplatinate (IV) | 16 | 0.600401 | 1.550776 | 0.040733196 | 0.2241297 | 0.681 | 648 | tags=38%, list=11%, signal=42% |
| 19 | Bisindolylmaleimide I | 23 | 0.587615 | 1.552711 | 0.030991735 | 0.2265287 | 0.679 | 964 | tags=39%, list=16%, signal=46% |
| 20 | Phytoestrogens | 16 | 0.768827 | 1.667617 | 0.022 | 0.2282088 | 0.462 | 856 | tags=63%, list=14%, signal=73% |
| 21 | Thapsigargin | 327 | 0.333608 | 1.533748 | 0.002061856 | 0.2255021 | 0.711 | 1303 | tags=34%, list=22%, signal=41% |
| 22 | 1-(5-deoxypentofuranosyl)-5-fluoropyrimidine-2,4 (1 h, 3 h)-dione | 23 | 0.565554 | 1.552936 | 0.0385439 | 0.2324028 | 0.679 | 1330 | tags=52%, list=22%, signal=67% |
| 23 | Nelfinavir | 18 | 0.513173 | 1.529705 | 0.029661017 | 0.2336185 | 0.716 | 1169 | tags=56%, list=19%, signal=69% |
| 24 | Vinblastine | 75 | 0.419995 | 1.523846 | 0.036885247 | 0.234146 | 0.724 | 995 | tags=31%, list=17%, signal=36% |
| 25 | Thimerosal | 53 | 0.525926 | 1.601744 | 0.018867925 | 0.2357184 | 0.592 | 1071 | tags=47%, list=18%, signal=57% |
| 26 | 67 | 0.455003 | 1.554736 | 0.017391304 | 0.2358129 | 0.675 | 1012 | tags=39%, list=17%, signal=46% | |
| 27 | Thalidomide | 61 | 0.512241 | 1.525544 | 0.025641026 | 0.2359595 | 0.719 | 1101 | tags=48%, list=18%, signal=58% |
| 28 | Protoporphyrin IX | 22 | 0.540459 | 1.536768 | 0.048625793 | 0.2360099 | 0.704 | 1355 | tags=50%, list=23%, signal=64% |
| 29 | Phosphine | 37 | 0.573179 | 1.534214 | 0.038793102 | 0.2361448 | 0.71 | 1479 | tags=51%, list=25%, signal=68% |
| 30 | Adenine | 25 | 0.575044 | 1.752054 | 0.007968128 | 0.2367139 | 0.286 | 650 | tags=40%, list=11%, signal=45% |
| 31 | Caffeic Acid | 24 | 0.516087 | 1.539089 | 0.032388665 | 0.2367951 | 0.7 | 1803 | tags=67%, list=30%, signal=95% |
| 32 | Lucanthone | 71 | 0.547325 | 1.609604 | 0.046653144 | 0.2390304 | 0.571 | 742 | tags=44%, list=12%, signal=49% |
| 33 | Dronabinol | 134 | 0.414731 | 1.603898 | 0.008230452 | 0.241325 | 0.586 | 1067 | tags=34%, list=18%, signal=40% |
| 34 | Antimony Potassium Tartrate | 37 | 0.50915 | 1.613491 | 0.012711864 | 0.24176 | 0.561 | 1181 | tags=49%, list=20%, signal=60% |
| 35 | Rottlerin | 35 | 0.511257 | 1.554947 | 0.020408163 | 0.2423282 | 0.674 | 1221 | tags=40%, list=20%, signal=50% |
| 36 | 62 | 0.493426 | 1.592946 | 0.022916667 | 0.2429922 | 0.604 | 874 | tags=44%, list=15%, signal=50% | |
| 37 | Rapamycin | 89 | 0.435861 | 1.58848 | 0.012765957 | 0.2433278 | 0.61 | 1346 | tags=45%, list=22%, signal=57% |
| 38 | Gefitinib | 33 | 0.622531 | 1.769392 | 0.006276151 | 0.2467885 | 0.242 | 753 | tags=42%, list=13%, signal=48% |
| 39 | Atenolol | 17 | 0.598956 | 1.667728 | 0.006012024 | 0.2487788 | 0.462 | 120 | tags=24%, list=2%, signal=24% |
| 40 | Antimony | 35 | 0.540104 | 1.615625 | 0.02096436 | 0.2491837 | 0.556 | 1181 | tags=51%, list=20%, signal=64% |
| 41 | Acrolein | 43 | 0.538176 | 1.555005 | 0.0392562 | 0.2494786 | 0.674 | 1067 | tags=47%, list=18%, signal=56% |
Notes: Column Headings as per GSEA website (https://software.broadinstitute.org/gsea/): Size; Number of genes in the gene set. Enrichment score for the gene set; the degree to which this gene set is overrepresented at the top or bottom of the ranked list of genes in the expression dataset. Normalized enrichment score; the enrichment score for the gene set after it has been normalized across analyzed gene sets. Nominal p-value; the statistical significance of the enrichment score. The nominal p-value is not adjusted for gene set size or multiple hypothesis testing; therefore, it is of limited use in comparing gene sets. False discovery rate; the estimated probability that the normalized enrichment score represents a false-positive finding. Familywise-error rate; a more conservatively estimated probability that the normalized enrichment score represents a false-positive finding. Rank at Max; the position in the ranked list at which the maximum enrichment score occurred. Three statistics are used to define the leading edge subset. Tags; the percentage of gene hits before (for positive ES) or after (for negative ES) the peak in the running enrichment score. This indicates the percentage of genes contributing to the enrichment score. List; the percentage of genes in the ranked gene list before (for positive ES) or after (for negative ES) the peak in the running enrichment score. This indicates where in the list, the enrichment score is attained. Signal, the enrichment signal strength that combines the two previous statistics.
The top enriched chemicals by GSEA categorized into different subgroups
| Occupational | Drugs | Plant/Plant toxins/Food |
|---|---|---|
| 1. Ammonium Hexachloroplatinate (IV) | 1. Nelfinavir | 1. Adenine |
| 2. Phosphine | 2. Thalidomide | 2. Arachidonic Acid |
| 3. Acrylamide | 3. Antimony Potassium Tartrate | 3. Baicalein |
| 4. 4-Hydroxytamoxifen | 4. Caffeic Acid | |
| 5. Acrolein | 5. SB 202190 ( | 6. Corilagin |
| 7. CLOFOP [ISO] ( | 6. Myricetin | 8. Curcumin |
| 7. Lucanthone | 9. Ellagic Acid | |
| 10. Bisindolylmaleimide I | 8. Dronabinol | 11. Luteolin |
| 12. Thapsigargin | 9. Rapamycin | 13. Microcystin RR |
| 14. MG-132 ( | 10. Atenolol | 15. Phytoestrogens |
| 16. DMNQ ( | 17. Protoporphyrin IX | |
| 18. Tyrphostin AG 538 | 19. Vinblastine | 20. Purpurogallin |
| 21. 1-(5-Deoxypentofuranosyl)-5-Fluoropyrimidine-2,4 (1 h, 3 h)-Dione | 22. 7-Amino-4-Hydroxy-2-Naphthalenesulfonic Acid | 23. Rottlerin |
| 24. Antimony | 25. Gefitinib | 26. Salazinic Acid |
List of pathways significantly associated with the largest number of the identified 41 chemicals using Comparative Toxicogenomics Database (CTD) batch query webtool (http://ctdbase.org/tools/batchQuery). Only pathways that are shared by more than 50% of the identified chemicals were listed
| Significant Chemicals Associated Pathways | Shared by how many chemicals (Total=41) | Percentage |
|---|---|---|
| Immune System | 33 | 80% |
| Cytokine Signaling in the Immune system | 31 | 76% |
| IL-17 signaling pathway | 31 | 76% |
| Pathways in cancer | 31 | 76% |
| Signaling by Interleukins | 31 | 76% |
| Signal Transduction | 31 | 76% |
| HTLV-I infection | 30 | 73% |
| Interleukin-4 and 13 signaling | 30 | 73% |
| Chagas disease (American trypanosomiasis) | 29 | 71% |
| Fluid shear stress and atherosclerosis | 29 | 71% |
| Hepatitis B | 29 | 71% |
| Innate Immune System | 29 | 71% |
| Metabolism | 29 | 71% |
| Apoptosis | 28 | 68% |
| Pertussis | 28 | 68% |
| TNF signaling pathway | 28 | 68% |
| Toxoplasmosis | 28 | 68% |
| Tuberculosis | 28 | 68% |
| AGE-RAGE signaling pathway in diabetic complications | 27 | 66% |
| Endocrine resistance | 27 | 66% |
| Gene Expression | 27 | 66% |
| MAPK signaling pathway | 27 | 66% |
| PI3K-Akt signaling pathway | 27 | 66% |
| Signaling by NGF | 27 | 66% |
| Viral carcinogenesis | 27 | 66% |
| Cellular responses to stress | 27 | 66% |
| Hemostasis | 27 | 66% |
| Herpes simplex infection | 27 | 66% |
| Non-alcoholic fatty liver disease (NAFLD) | 27 | 66% |
| Platinum drug resistance | 27 | 66% |
| MicroRNAs in cancer | 26 | 63% |
| NOD-like receptor signaling pathway | 26 | 63% |
| Proteoglycans in cancer | 26 | 63% |
| Toll-like receptor signaling pathway | 26 | 63% |
| Amoebiasis | 26 | 63% |
| HIF-1 signaling pathway | 26 | 63% |
| Influenza A | 26 | 63% |
| Legionellosis | 26 | 63% |
| Progesterone-mediated oocyte maturation | 26 | 63% |
| Prostate cancer | 26 | 63% |
| Amyotrophic lateral sclerosis (ALS) | 25 | 61% |
| Adaptive Immune System | 25 | 61% |
| Bladder cancer | 25 | 61% |
| Cell cycle | 25 | 61% |
| Colorectal cancer | 25 | 61% |
| Downstream signaling events of B Cell Receptor (BCR) | 25 | 61% |
| Generic Transcription Pathway | 25 | 61% |
| Leishmaniasis | 25 | 61% |
| Senescence-Associated Secretory Phenotype (SASP) | 25 | 61% |
| FoxO signaling pathway | 25 | 61% |
| Measles | 25 | 61% |
| p53 signaling pathway | 25 | 61% |
| Rheumatoid arthritis | 25 | 61% |
| Developmental Biology | 24 | 59% |
| Downstream signal transduction | 24 | 59% |
| Epstein-Barr virus infection | 24 | 59% |
| Estrogen signaling pathway | 24 | 59% |
| Fc epsilon receptor (FCERI) signaling | 24 | 59% |
| Metabolism of lipids and lipoproteins | 24 | 59% |
| NGF signaling via TRKA from the plasma membrane | 24 | 59% |
| Osteoclast differentiation | 24 | 59% |
| Signaling by EGFR | 24 | 59% |
| Signaling by PDGF | 24 | 59% |
| Th17 cell differentiation | 24 | 59% |
| Toll-Like Receptors Cascades | 24 | 59% |
| Cellular Senescence | 24 | 59% |
| Insulin resistance | 24 | 59% |
| Interleukin-10 signaling | 24 | 59% |
| Transcriptional misregulation in cancer | 24 | 59% |
| Transcriptional Regulation by TP53 | 24 | 59% |
| Cell Cycle, Mitotic | 24 | 59% |
| Activated TLR4 signalling | 23 | 56% |
| Breast cancer | 23 | 56% |
| Central carbon metabolism in cancer | 23 | 56% |
| DAP12 interactions | 23 | 56% |
| DAP12 signaling | 23 | 56% |
| MyD88 cascade initiated on the plasma membrane | 23 | 56% |
| MyD88 dependent cascade initiated on endosome | 23 | 56% |
| MyD88-independent TLR3/TLR4 cascade | 23 | 56% |
| MyD88:Mal cascade initiated on plasma membrane | 23 | 56% |
| Neurotrophin signaling pathway | 23 | 56% |
| Prolactin signaling pathway | 23 | 56% |
| Salmonella infection | 23 | 56% |
| Signaling by SCF-KIT | 23 | 56% |
| Th1 and Th2 cell differentiation | 23 | 56% |
| Toll Like Receptor 10 (TLR10) Cascade | 23 | 56% |
| Toll-Like Receptor 2 (TLR2) Cascade | 23 | 56% |
| Toll-Like Receptor 3 (TLR3) Cascade | 23 | 56% |
| Toll-Like Receptor 5 (TLR5) Cascade | 23 | 56% |
| Toll-Like Receptor 7/8 (TLR7/8) Cascade | 23 | 56% |
| Toll-Like Receptor 9 (TLR9) Cascade | 23 | 56% |
| Toll-Like Receptor TLR1: TLR2 Cascade | 23 | 56% |
| Toll-Like Receptor TLR6: TLR2 Cascade | 23 | 56% |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 23 | 56% |
| TRIF-mediated TLR3/TLR4 signaling | 23 | 56% |
| Chronic myeloid leukemia | 23 | 56% |
| Cytokine-cytokine receptor interaction | 23 | 56% |
| Disease | 23 | 56% |
| Hepatitis C | 23 | 56% |
| Inflammatory bowel disease (IBD) | 23 | 56% |
| Pancreatic cancer | 23 | 56% |
| Signaling by the B Cell Receptor (BCR) | 23 | 56% |
| Alzheimer’s disease | 23 | 56% |
| Cell Cycle | 23 | 56% |
| ErbB signaling pathway | 22 | 54% |
| FCERI mediated MAPK activation | 22 | 54% |
| GAB1 signalosome | 22 | 54% |
| Metabolism of proteins | 22 | 54% |
| PI3K/AKT activation | 22 | 54% |
| PIP3 activates AKT signaling | 22 | 54% |
| Shigellosis | 22 | 54% |
| Signaling by VEGF | 22 | 54% |
| T cell receptor signaling pathway | 22 | 54% |
| Toll-Like Receptor 4 (TLR4) Cascade | 22 | 54% |
| VEGF signaling pathway | 22 | 54% |
| Apoptosis | 22 | 54% |
| Diseases of signal transduction | 22 | 54% |
| Epithelial cell signaling in Helicobacter pylori infection | 22 | 54% |
| Intrinsic Pathway for Apoptosis | 22 | 54% |
| Malaria | 22 | 54% |
| Mitotic G1-G1/S phases | 22 | 54% |
| NF-kappa B signaling pathway | 22 | 54% |
| Programmed Cell Death | 22 | 54% |
| Ras signaling pathway | 22 | 54% |
| Small cell lung cancer | 22 | 54% |
| Prion diseases | 22 | 54% |
| Activation of the AP-1 family of transcription factors | 21 | 51% |
| Autophagy - animal | 21 | 51% |
| B cell receptor signaling pathway | 21 | 51% |
| cAMP signaling pathway | 21 | 51% |
| Endometrial cancer | 21 | 51% |
| MAPK family signaling cascades | 21 | 51% |
| Thyroid hormone signaling pathway | 21 | 51% |
| VEGFA-VEGFR2 Pathway | 21 | 51% |
| Acute myeloid leukemia | 21 | 51% |
| Adipocytokine signaling pathway | 21 | 51% |
| Apoptosis - multiple species | 21 | 51% |
| Chemokine signaling pathway | 21 | 51% |
| EGFR tyrosine kinase inhibitor resistance | 21 | 51% |
| Glioma | 21 | 51% |
| Jak-STAT signaling pathway | 21 | 51% |
| Longevity regulating pathway | 21 | 51% |
| Oxidative Stress-Induced Senescence | 21 | 51% |
| Renal cell carcinoma | 21 | 51% |
| Role of LAT2/NTAL/LAB on calcium mobilization | 21 | 51% |
| Sphingolipid signaling pathway | 21 | 51% |
| Platelet activation, signaling, and aggregation | 21 | 51% |